Prognostic Implications of Neutropenia in Advanced Gastric Cancer: An Exploratory Analysis of the RINDBeRG Trial

Predictive Value of Nivolumab-Free Interval in Ramucirumab Plus Irinotecan Therapy: An Exploratory Analysis of the RINDBeRG Trial

胃癌術後補助化学療法時の栄養介入が予後に与える影響（OGSG1108試験の追加観察研究）

Phase I/II study of neoadjuvant chemoradiotherapy consisting of S-1 and cisplatin for patients with clinically resectable type 4 and large type 3 gastric cancer (OGSG1205)

Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for patients with large type 3 or type 4 gastric cancer: final outcomes of a multicenter, phase II study (OGSG 1902)

Efficacy and safety of irinotecan-based therapy in elderly patients with advanced gastric cancer receiving third-line or later chemotherapy: post-hoc age-subgroup analysis of the rindberg trial

ASTRON (OGSG 2401) study protocol: Ferric carboxymaltose for iron deficiency anemia in gastrointestinal cancer

Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial

Phase II Trial of Capecitabine Plus Bevacizumab for Elderly Patients With Metastatic Colorectal Cancer: OGSG 1102

Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery followed by adjuvant docetaxel and S-1 for patients with large type 3 or type 4 gastric cancer: Short-term outcomes of the phase II OGSG1902 trial